Sequential immunotherapy framework

Video transcript 

(light music) [Narrator]

Francisco Ramirez-Valle: A sequential immunotherapy framework informed by advances in the understanding of human biology aims to rebalance the immune system in patients living with immune-mediated diseases.

Step one is to control inflammation, or treat symptoms. This is accomplished through targeted immune inhibition and is where most currently available therapies focus. These therapies can lead to undesired broad immunosuppression and increased risk for infection, and they don't work in all patients. However, the opportunity exists to innovate through a precision medicine approach.

Step two aims to reset the immune system by eliminating pathogenic immune-memory cells. We believe this can be achieved by depleting autoreactive cells or by promoting immune tolerance. Cell therapy is a platform that has shown early promise in achieving an immune reset and is being explored further.

Finally, the goal of step three is to maintain immune homeostasis and promote tissue repair. This important step helps sustain remission over time by leveraging regulatory mechanisms in the body.

At Bristol Myers Squibb, we believe this sequential immunotherapy approach is enabled by our emphasis on causal human biology. Matched with expertise across an array of innovative modalities, this strategy has the potential to deliver transformational advances for patients, including durable remissions and cures.